MedTrace Logo

Rescue FMT with Bezlotoxumab for Recurrent C. Difficile Infection

NCT06669936 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-11-01

No results posted yet for this study

Summary

The goal is to evaluate the benefit of adding bezlotoxumab to repeat fecal microbiota transplantation (FMT) in patients with recurrent Clostridioides difficile infections after failure of FMT alone.

Conditions

  • Recurrent C. Difficile Infection

Interventions

DRUG

Fecal microbiota transplantation ± bezlotoxumab

Co-administration of bezlotoxumab and FMT in patients with recurrent C. difficile infections who failed FMT alone.

Sponsors & Collaborators

  • Alexander Khoruts

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2024-10-01
Completion
2024-10-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06669936 on ClinicalTrials.gov